Australia's Neuren Pharma climbs after Canada approves drug trial

Neuren Pharmaceuticals

21/12/2025 23:28

** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 2.8% to A$20.13

** Biopharma firm announces Health Canada has approved its Clinical Trial Application (CTA) for the Koala Phase 3 clinical trial of NNZ-2591 in treatment of Phelan-McDermid syndrome, a rare genetic condition that affects brain development

** CTA approval enables inclusion of clinical trial sites in Canada

** NEU up 59.4% YTD

Health Canada has approved Neuren’s Clinical Trial Application (CTA) for the Koala Phase 3

 (Reporting by Keshav Singh Chundawat in Bengaluru; Editing by Edmund Klamann)

 ((Keshav.singhchundawat@thomsonreuters.com))